|
|
 |
|
Viewing report
|
|
|
|
Ion Channels as Therapeutic Targets for Multiple Diseases
Bioseeker, Nov 2002
Ion channels play an important role in numerous cell types and occur as large families of related genes with cell-specific expression patterns. Considering the publication of the human genome and the progress in transcription profiling revealing the tissue specific distributions of ion channels, they will play a much more important role as therapeutic drug targets in the future. These advancements combined with cell-based assays providing biologically relevant information to genomic and proteomic information will make ion channels a favorable class of selective, tissue specific, drug targets. Currently, there are active pharmaceutical research and development programs involving ion channels in a number of areas, including asthma, inflammation, arrhythmia and CNS disorders
Several disease states are related to dysfunctional ion channels. Among prominent groups are cardiac arrhythmias, diabetes, hypertension, angina pectoris and epilepsy. Several drugs already marketed have generated substantial revenues for the companies.
Already today, drugs targeting ion channels generates over 6 billion dollars in sales per annum. According to the FDA, the number of new approved drugs targeting ion channels is equal to or even higher than that for drugs targeting proteases, polymerases and reverse transcriptases. But, inspite of their remarkable physiological value, ion channels have stayed a relatively unexploited therapeutic target class, especially in comparison to target areas such as G-protein coupled receptors or kinases. Major challenges for high throughput screening (HTS) with high information content have been the main limiting factor for an explosion in R&D.
BioSeeker Group AB has recognized the interest and need for a continuous surveillance within the field of ion channels as targets for drug discovery. This report includes market outlooks and updated information on ion channel targets related to diseases such as urinary incontinence, multiple sclerosis, diabetes, inflammation, pain and CNS disorders such as epilepsy and depression. Scientific advancements are presented in relation to each disease group. Further, the report comments on new ion channel drug discovery technologies.
Technological breakthroughs have been made for drug discovery tools applied in the hunt for novel therapeutics targeting ion channels. BioSeeker Group has in identified improvements for new drug discovery platforms that have the potential for substantially improve HTS. According to a distinguished scientist and product developers, technologies will have to change to collect more data on each individual experiment and a need for more human settings is also clear. Technologies such as molecular targeting imaging with local electrical data and 3D-anatomical pictures will probably be tools frequently used in the future.
The report also includes a coverage of the conference Ion Channels in drug discovery and development held 24-25 October this year. Key alliances and company activities are also described
Apart from the pharma industry itself, this report is of value to investors, science incubators, investigators, contract research organizations or any other types of organization that have an interest in new antifungal therapies.
Companies Included in this Report
Abbott Laboratories, Amersham BioSciences, Asta Medica, AstraZeneca, Aurora BioSciences, Aviva Biosciences, Axon Instruments, Axxam s.r.l, Bayer, Caliper Technologies, Cellectricon AB, CeNeS Pharmaceuticals, Elan Pharmaceuticals, Essen Instruments, Evotec/Genion, Icagen Inc, Merck, Molecular Devices/Cytion, Nanion Technologies, Neuromed Technologies Inc, Neurosearch, Nimbus Biotechnology, Novartis, Parion Sciences, RW Johnson Pharmaceutical Research Institute, Schering-Plough, Sophion Bioscience, Wyeth Corp, Xention Discovery.
Customers who bought this item also bought
Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies
Ion Channel Drug Discovery - Therapeutic Opportunities & Technology Progress
Phosphatases: Emerging Role in Signal Transduction, Human Therapeutics, & As Drug Targets
Ion Channel Assays in the Drug Discovery Process
Metal-Based Neurodegeneration: From Molecular Mechanisms To Therapeutic Strategies
The Emerging Drug Targets Outlook: An Analysis of Novel Molecular Targets To Develop Innovative New Therapeutics
Rheumatoid arthritis: Emerging drug discovery targets and therapeutic candidates
Atrial Fibrillation: Emerging Drug Discovery Targets and Therapeutic Candidates
|
|
|
|
